To assess the health effects of transferral to low-exposure jobs on subjects with occupational asthma (OA).
We performed a cross-sectional survey of 83 workers in 2 platinum (Pt) refineries and 2 catalyst production plants, all with diagnosed OA due to Pt salts.
In all, 9 workers (group A ; 11%) continued to be exposed at the time of examination, 16 subjects (group B ; 19%) had been transferred to other workplaces within the production building, 39 subjects (group C ; 47%) had been transferred to areas outside the building but inside the plant, and 19 subjects (group D : 23%) had left the plant.
The median period from transferral to examination was 54 months (lower quartile 23 months, upper quartile 84 months, n=74).
Symptoms, skin-prick tests (SPT) with environmental allergens and Pt salt, total serum IgE, lung function, and bronchial hyperresponsiveness were assessed by standard procedures.
Asthma symptoms were reported by all subjects in the production area but by only 37 of 74 subjects (50%) after transferral, with no difference being found between groups B, C. and D. Both the proportion of subjects sensitized to Pt salts (100%, 88%, 67%, and 42% in groups A, B. C. and D. respectively) and the degree of sensitization were associated with exposure (P<0.0002).
Total IgE was higher in group A as compared with groups B. C. or D (P<0.002).
There was no association between bronchial hyperresponsiveness and exposure. (...)
Mots-clés Pascal : Exposition professionnelle, Médecine travail, Platine composé, Industrie métal précieux, Maladie professionnelle, Asthme, Allergie, Teneur air ambiant, Poste travail, Transfert, Pronostic, Evolution, Symptomatologie, Etude cohorte, Homme, Appareil respiratoire pathologie, Bronchopneumopathie obstructive, Immunopathologie
Mots-clés Pascal anglais : Occupational exposure, Occupational medicine, Platinum compound, Precious metal industry, Occupational disease, Asthma, Allergy, Ambient air concentration, Workplace layout, Transfer, Prognosis, Evolution, Symptomatology, Cohort study, Human, Respiratory disease, Obstructive pulmonary disease, Immunopathology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0092776
Code Inist : 002B03L05. Création : 31/05/1999.